drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Genetically engineered natural killer (NK) cells expressing an anti-CD19 chimeric antigen receptor to recognize and eliminate CD19+ B cells via NK cytotoxic pathways, intended to deplete autoreactive B cells/plasmablasts in refractory ITP.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered natural killer (NK) cells expressing an anti-CD19 chimeric antigen receptor selectively bind CD19 on B cells/plasmablasts and eliminate them via NK cytotoxic pathways (perforin/granzyme release and death receptor signaling), depleting autoreactive B cells to reduce pathogenic autoantibody production in refractory ITP.
drug_name
KN5501 (anti-CD19 CAR NK cells)
nct_id_drug_ref
NCT06337474